nifedipine has been researched along with Retinitis Pigmentosa in 8 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Retinitis Pigmentosa: Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the long-term effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)." | 9.17 | Long-term effects of nilvadipine against progression of the central visual field defect in retinitis pigmentosa: an extended study. ( Ito, T; Kudo, T; Metoki, T; Nakazawa, M; Ohguro, H; Suzuki, Y, 2013) |
| "To assess the effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)." | 9.15 | Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. ( Ito, T; Metoki, T; Miyagawa, Y; Nakazawa, M; Ohguro, H; Takeuchi, K, 2011) |
| "To assess the long-term effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)." | 5.17 | Long-term effects of nilvadipine against progression of the central visual field defect in retinitis pigmentosa: an extended study. ( Ito, T; Kudo, T; Metoki, T; Nakazawa, M; Ohguro, H; Suzuki, Y, 2013) |
| "To assess the effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)." | 5.15 | Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. ( Ito, T; Metoki, T; Miyagawa, Y; Nakazawa, M; Ohguro, H; Takeuchi, K, 2011) |
| "Nilvadipine was administered from P7 to P28." | 1.37 | AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency. ( Allocca, M; Auricchio, A; Di Vicino, U; Iodice, C; Manfredi, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakazawa, M | 5 |
| Suzuki, Y | 1 |
| Ito, T | 2 |
| Metoki, T | 5 |
| Kudo, T | 1 |
| Ohguro, H | 6 |
| Takeuchi, K | 1 |
| Miyagawa, Y | 2 |
| Sakamoto, K | 1 |
| Mori, A | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Allocca, M | 1 |
| Manfredi, A | 1 |
| Iodice, C | 1 |
| Di Vicino, U | 1 |
| Auricchio, A | 1 |
| Sato, M | 1 |
| Ohguro, I | 2 |
| Mamiya, K | 2 |
| Takano, Y | 3 |
| Yamazaki, H | 3 |
| Ishikawa, F | 2 |
| Dezawa, M | 2 |
| Ishikawa, H | 1 |
| Maeda, T | 1 |
| Maruyama, I | 1 |
| Sawada, H | 1 |
2 reviews available for nifedipine and Retinitis Pigmentosa
| Article | Year |
|---|---|
[Cause of retinitis pigmentosa and new therapeutics under development].
Topics: Animals; c-Mer Tyrosine Kinase; Carrier Proteins; cis-trans-Isomerases; Cyclic Nucleotide Phosphodie | 2011 |
[New drug therapy for retinal degeneration].
Topics: Animals; Calcium Channel Blockers; Dark Adaptation; Disease Models, Animal; Humans; Mice; Mutation; | 2008 |
2 trials available for nifedipine and Retinitis Pigmentosa
| Article | Year |
|---|---|
Long-term effects of nilvadipine against progression of the central visual field defect in retinitis pigmentosa: an extended study.
Topics: Adult; Aged; Calcium Channel Blockers; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nifedip | 2013 |
Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial.
Topics: Administration, Oral; Adult; Aged; Calcium Channel Blockers; Disease Progression; Female; Follow-Up | 2011 |
4 other studies available for nifedipine and Retinitis Pigmentosa
| Article | Year |
|---|---|
AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency.
Topics: Animals; Calcium Channel Blockers; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Cycli | 2011 |
Study of pharmacological effects of nilvadipine on RCS rat retinal degeneration by microarray analysis.
Topics: Animals; Apoptosis; Blotting, Western; Calcium Channel Blockers; Cell Death; Fibroblast Growth Facto | 2003 |
Study of drug effects of calcium channel blockers on retinal degeneration of rd mouse.
Topics: Animals; Calcium Channel Blockers; Caspases; Diltiazem; Electroretinography; Fibroblast Growth Facto | 2004 |
Preservation of retinal morphology and functions in royal college surgeons rat by nilvadipine, a Ca(2+) antagonist.
Topics: Animals; Blotting, Western; Calcium Channel Blockers; Caspase 1; Caspase 2; Caspases; Crystallins; D | 2002 |